FT Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: Results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial

European Heart Journal

Volumn 25, Issue 10, 2004, Pages 837-846

  Van't Hof, Arnoud W J ^a   Ernst, Nicolette ^a   De Boer, Menko Jan ^a   De Winter, Rob ^b   Boersma, Eric ^c   Bunt, Ton ^d   Petronio, Sonia ^e   Gosselink, A T Marcel ^a   Jap, Walter ^f   Hollak, Frans ^g   Hoorntje, Jan C A ^a   Suryapranata, Harry ^a   Dambrink, Jan Henk E ^a   Zijlstra, Felix ^a  

^a ISALA HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f GELRE HOSPITALS   (Netherlands)

^g Ambulance Dienst   (Netherlands)

Author keywords

Anti platelet therapy; Primary angioplasty; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TYROSINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHRONOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; DRUG ANTAGONISM; FOLLOW UP; HEART INFARCTION; METHODOLOGY; MIDDLE AGED; PATIENT TRANSPORT; TIME; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TRANSPORTATION OF PATIENTS; TREATMENT OUTCOME; TYROSINE;

EID: 4444329389     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.04.003     Document Type: Article

References (32)

1. Zijlstra F, Hoorntje JCA, de Boer MJ et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-9.
2. Grines C, Patel A, Zijlstra F et al., PCAT collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.
3. Zijlstra F. Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur Heart J 2003;24:21-3.
4. Andersen HR, Nielsen TT, Rasmussen K et al., DANAMI-2 investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.
5. Widimsky P, Budesinsky T, Vorac D et al., for the "PRAGUE" study group investigators. Long distance transport for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicenter trial "PRAGUE-2". Eur Heart J 2003;23:94-104.
6. Brodie BR, Stuckey TD, Hansen C et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:13-8.
7. Stone GW, Cox D, Garcia E et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Circulation 2001;104:636-41.
8. Gold HK, Garabedian HD, Dinsmore RE et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997;95:1755-9.
9. van den Merkhof LF, Zijlstra F, Olsson H et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999;33:1528-32.
10. Antman EM, Gibson CM, de Lemos JA et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000;21:1944-53.
11. Herrmann HC, Moliterno DJ, Ohman EM et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489-96.
12. Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:723-5.
13. Mabin TA, Holmes Jr DR, Smith HC et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5:198-202.
14. Gibson CM, Cannon CP, Daley WL et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
15. Van't Hof AWJ, Liem A, Suryapranata H, on behalf of the Zwolle myocardial infarction study group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998;97:2302-6.
16. Morrow DA, Antman EM, Charlesworth A et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7.
17. Montalescot G, Barragan P, Wittenberg O et al., for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
18. Lee DP, Herity NA, Hiatt BL et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tlrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497-501.
19. Arntz H, Schröder J, Pels K et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. Eur Heart J 2003;23 (abstract): 1502.
20. Schneider DJ, Herrmann HC, Lakkis N et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003;91:334-6.
21. White CJ, Ramee SR, Collins TJ et al. Coronary thrombi increase PTCA risk. Circulation 1996;93:253-8.
22. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 2002;122:1322-32.
23. Fukuda D, Tanaka A, Shimada K et al. Predicting angiographic distal embolization following percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol 2003;91:403-7.
24. Ross AM, Coyne KS, Reiner JS et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-62.
25. Vermeer F, Oude Ophuis AJ, vd Berg EJ et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31.
26. Widimsky P, Groch L, Zelizko M, on behalf of the PRAGUE Study Group Investigators. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-31.
27. Kastrati A, Mehilli J, Schlotterbeck K et al. Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-54.
28. Zijlstra F, Ernst N, de Boer MJ et al. Influence of pre-hospital administration of aspirin and heparin on initial patency of the infarct related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002;39:1733-7.
29. De Luca G, Ernst N, Zijlstra F et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004;43:1363-7.
30. De Luca G, Suryapranata H, Ottervanger JP et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-5.
31. Boersma E, Mercado N, Poldermans D et al. Acute myocardial infarction. Lancet 2003;361:847-58.
32. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.